

DAFTAR PUSTAKA

- Aberer, W., Bircher, A., Romano, A., Blanca, M., Campi P, Fernandez J. 2003. Drug provocation testing in the diagnosis of drug hypersensitivity reactions. *Allergy*, 58, 854-863.
- Aberer, W., Kranke, B. 2008. Clinical manifestations and mechanisms of skin reaction after systemic drug administration. *Drug Discovery Today: Disease Mechanism*. 5, 237-247.
- Adam, J., Pichler, WJ., Yery, D. 2011. Delayed drug hypersensitivity: models of T cell stimulation. *Br J Clin Pharmacol*, 71, 701-707.
- Ahmed, AM., Pritchard, S., Reichenberg, J.A. 2013. review of cutaneous drug eruptions. *Clinics in geriatric medicine*, 29(2):527-45.
- Ajayi FO, Sun H, Peryy J. 2008. Adverse drug reactions: A review of relevant factors. *J Clin Pharmacol*, 40, 1092-1101.
- Anderson., JR. 2014. *Nevirapine and the quest to end pediatric AIDS*. 1st Edition pp.110-113, New York, McFarland.
- Arden-Jones, MR., Friedmann, PS., 2011. Skin manifestations of drug allergy. *Br J Pharmacol*, 71(5), 672-683.
- AIDS Info, 2014. The Evidence that HIV causes AIDS, national institute of Allergy and infectious diseases.
- Barbaud, A., Reichert-Penetrat, S., Trechot, P. 1998. The use of skin testing in the investigation of cutaneous adverse drug reactions. *British Journal of dermatology*, 139, 49- 58.
- Barbaud, A., Goncalo, M., Bruynzeel, D., Bircher, A. 2001. Guidelines for performing skin test drugs in the investigation of cutaneous adverse. *Contact Dermatitis*, 45, 321-328.
- Barbaud, A. 2003. Usefulness of drug patch testing cutaneous drug allergy: What is new? *Revue francaise d'allergologie et d'immunologie clinique*, 43, 222-226.
- Barbaud, A. 2005. Drug patch testing in systemic cutaneous drug allergy. *Toxicology*, 209, 209-216
- Barbaud, A., Collet, E., Milpied, B., Assier, H., Staumont, D., Avenel A. *et al.* 2013. A multicentre study to determine the value and safety of drug patch tests for the three main classes of severe cutaneous adverse drug reaction. *Br J Dermatol*, 168, 555-562
- Baratawidjaja, KG. 2000. *Imunologi Dasar*, edisi IV. Jakarta: Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Baratawidjaja & Rengganis, I. 2014. *Imunologi Dasar*, edisi ke 11. Badan Penerbit Fakultas Kedokteran Universitas Indonesia.
- Bigby, M. 2001. Rates of cutaneous reactions to drugs. *Arch Dermatol*. 137, 765-770.
- Borchers, A., Lee, J., Naguwa, S., Cheema, G., Gershwin, M. 2008. Sindrom Stevens Johnson and Nekrolisis Epidermal Toksik. *Autoimmunity Reviews*. 7:598-605.

- Boehringer Ingelheim, 2005. *Viramune® (nevirapine) Tablets & Oral Suspension*, Ridgefield.
- Brockow, K., Romano, A., Blanca, M., Blanca, M., Ring J, Pichler, W 2000. General consideration for skin test procedures in the diagnosis of drug hypersensitivity. *Allergy*. 57 (1) 45-51.
- Britschgi, M., Steiner, UC., Schmid, S., Depta, JP., Senti, G., Bircher, A. 2001. T-cell involvement in drug induced acute generalized exanthematous pustulosis. *J Clin Invest*, 107, 1433-1441.
- Caar, A., Cooper, DA. 2000. Adverse effects of antiretroviral therapy. *Lancet* 356:1423-30.
- Chatterjee, S & Ghosh, AP., Barbhuiya, J. 2006. Adverse cutaneous drug reactions in hospitalized patients: A meta-analysis of prospective studies. *JAMA*, 279, 1200-1205.
- Challener, Cynthia A. 2017. Oral Delivery of Biologic: The Challenge Continues. *PharmTech Home*
- Chen, LF., Hoy, J and Lewin, SR. 2007. Ten years of highly active antiretroviral therapy for HIV infection. *Med J Aust* 186 (3): 146-51.
- Chaponda, M., Pirmohamed, M. 2010. Hypersensitivity reactions to HIV therapy. *Br J Clin Pharmacol* 71(5):659-671.
- Cheeseman, SH., Hattox, SE., McLaughlin, MM., Koup, RA., Andrews, C., Bova, CA. *et al.* 1993. Pharmacokinetics of nevirapine: initial single-rising-dose study in humans. *Antimicrob Agents Chemother*. 37:178-82.
- Chudasama AS, Patel VV, Nivsarkar M, Vasu KK, and Shishoo CJ. 2014. *In vivo* Evaluation of Self Emulsifying Drug Delivery System for Oral Delivery of Nevirapine. *Indian J Pharm Sci*. May-Jun; 76(3): 218-24.
- Depkes RI (2009). Profil Kesehatan Indonesia. Jakarta: Departemen Republik Indonesia.
- De Maat, MM., Heine, R., Mulder, JW., Meenhorst PL., Mairuhu, AT., van Gorp, Huitema, A. *et al.* 2003. Incidence and risk factors for nevirapine-associated rash. *Eur J Clin Pharmacol*. 59(5-6):457-62.
- Dickinson, L. 2014. Population Pharmacokinetic and Pharmacogenetic Analysis of Nevirapine in Hypersensitive and Tolerant HIV-Infected Patients from. *Antimicrobial Agents and Chemotherapy*, 58(2), pp.706- 712.
- Dolin, R., Masur, H., Saag, MS. 2007. AIDS therapy, New York, *Elsevier*. 3rd Edition pp. 233-244.
- Elias PM. 2005. Physiologic lipids for barrier repair in dermatology. In: Elias PM, ed. *Skin Barrier*. New York: Taylor & Francis; p 337-61.
- Empedrad, R., Darter, Al., Earl, HS., Gruchalla, RS. 2003. Non irritating intradermal skin test concentrations for commonlu prescribed antibiotics. *J Allergy Clin Immunol*, 112, 629-630.
- Farquharson, NR. 2013. Drug eruptions. *Medicine*. 41(6):360-4.
- Florida, M., Bucciardini, R., Fragola, V., Galluzo, CM., Giannini, G., Pirillo MF. *et al*, 2004. Risk factors and occurrence of rash in HIV-positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside-experienced patients with very low CD4 levels (<50 cells/microL). *HIV Med*. 5(1):1-10.

- Fonacier, L & Brook, S. 2015. A Practical Guide to Patch Testing. *The Journal of Allergy and Clinical Immunology in Practice*, 1-7.
- Gaffar A. 2006. Hypersensitivity reactions. Dalam Male D, Brostoff J, Roth D and Roitt I. *Immunology*. 7th Edition pp.23-26., New York, Mosby, Elsevier
- Goncalo, M., Bruynzeel, DP. 2011. Patch testing in adverse drug reactions. In: Johansen JD, editors. *Contact Dermatitis*. Berlin: Springer-Verlag Berlin Heidelberg, 475-491.
- Giorgini, S., 2011 Use of Patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients, *Dermatol Ther*, 24(6):591-4.
- Grandhe, NP., Kaur, I., Parsad, D., Dogra, S. 2004. Role of patch testing in antimicrobial drug eruptions. *Contact Dermatitis*, 50, 259-61.
- Hausmann, O., Schnyder, B., Pichler, WJ. 2010. Drug Hypersensitivity Reactions Involving Skin. In Uetrecht J.(ed). *Adverse Drug Reactions. Handbook of Experimental Pharmacology*. Springer, New York. 29-55.
- Havlir, D., McLaughlin, MM., Reichman, DD. 1995. A pilot study to evaluate the development of resistance to nevirapine in asymptomatic human immunodeficiency virus-infected patients with CD4 cell counts of >500/mm³: AIDS Clinical Group Protocol 208. *J Infect Dis*. 172: 1379-83.
- Hargrave, KD., Proudfoot, JR., Grozinger, KG., Cullen, E., Kapadia, SR., Patel, UR. *et al*. 1991. Novel non-nucleoside inhibitors of HIV-1 reverse transcriptase. 1. Tricyclic pyridobenzo- and dipyridodiazepinones. *J Med Chem*. 34(7):2231-41.
- Husain, Z., Reddy, BY., Schwartz, RA., Edin F. 2013. DRESS syndrome Part I. Clinical perspectives. *Journal of American Dermatology*. 68(5):693e1-14.
- Kappelhoff BS, Huitema AD, Leth F, Robinson PA, MacGregor TR, Lange JM, Beijnen JH. 2005. Pharmacokinetics of nevirapine:once-daily versus twice-daily dosing in the 2 study. *HIV Clin Trials*. 6(5):254-61.
- Kemenkes RI. 2011. *Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral pada Orang Dewasa*. Kementerian kesehatan Republik Indonesia-Direktorat Jenderal Pengendalian Penyakit dan penyehatan Lingkungan. Jakarta.
- Kemenkes RI, 2012. Pedoman nasional tatalaksana klinis infeksi HIV dan terapi antiretroviral. Kementerian Kesehatan Republik Indonesia, Jakarta.
- Kemenkes RI, 2014. Infodatin : Pusat Data dan Informasi Kementerian Kesehatan RI. , pp.1-6.
- Kemenkes RI. 2015. Pedoman Nasional Tatalaksana Klinis Infeksi HIV dan Terapi Antiretroviral. Kementerian kesehatan Republik Indonesia-Direktorat Jenderal Pengendalian Penyakit dan penyehatan Lingkungan. Jakarta.
- Khan, DA & Solensky, R. 2010. Drug allergy. *Journal of Allergy Clinical Immunology*, 125, S126- 137.
- Khan, KUK., Khan, AH., Sulaiman, SH., Soo, CT., Aftab, RA. 2014. Adverse effect of highly active anti-retroviral therapy (HAART) in HIV/AIDS patients, *Indian J Pharm Parct*, 29-34.

- Kimia Farma. 2012. Rincian produk. http://www.kimiafarma.co.id/?page=product_detail&cat=4&subcat=409&prod=169. diakses 28 Desember 2017.
- Knowles, SR., Shapiro, LE., Shear, NH. 1999. Anticonvulsant hypersensitivity syndrome: incidence, prevention and management. *Drug Saf.* Dec; 21(6): 489-501.
- Lachapelle, JM & Maibach, H.I. 2009. *Patch Testing and Prick Testing, A Practical Guide Official Publication of the ICDRG second*. Springer-Verlag Berlin Heidelberg.
- Likanonsakul, S., Rattanatham, T., Feangvad, S., Uttayamakul, S., Prasithsirikul, W., Tunthanathip, P. *et al.* 2009. HLA-Cw*04 allele associated with nevirapine-induced exantema in HIV-infected Thai patients. *AIDS Res Ther.* 6:22.
- Lindberg, M., Matura, M. 2011. Patch testing. In: Johansen JD, editors. *Contact Dermatitis*. Berlin: Springer-Verlag Berlin Heidelberg, 439-460.
- Lachapelle, JM. 2009. Testing procedures in cutaneous adverse reactions. In: Lachapelle JM, Maibach HI, editors. *Patch testing and prick testing: A practical guide*. Springer-Verlag Berlin Heidelberg, p.155-166.
- Mahajan KV, Handa S. 2013. Patch testing in cutaneous drug reactions: methodology, interpretation, and clinical relevance. *Indian J Dermatol, Venereol, and Leprology*, 79, 836-41.
- Malal S, Phillips E, Carosi G. 2008. HLA-B*5701 screening for hypersensitivity to abacavir. *NEngl J Med*: 358: 568-579.6
- Marinho, Acharjya B. 2013. Adverse cutaneous drug reaction. *Indian J Dermatol*, 53, 2-8.
- Mirakian, R., Ewan, PW., Durham, SR., Youlten, L.J.F., Dugue, P., Friedmann PS, *et al.* 2010. BSACI guidelines for the management of the drug allergy. *Clin Exp Allergy*, 39, 43-61.
- Milpied-Homsy, B., Moran, E.M. & Phillips, E.J. 2015. Antiviral Drug Allergy. *Immunol Allergy Clin North Am*, 34(3), pp.645-662.
- Montaner, JS., Reiss, P., Cooper, D., Vella, S., Harris, M., Conway, B.1998. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients. *JAMA*; 279:930-7.
- Nayak, S., Acharjya, B. 2008. Adverse cutaneous drug reaction. *Indian J Dermatol*, 53, 2-8.
- Neupane, S., Sharma, SR. 2012. Cutaneous adverse drug reactions: a 6-month teaching hospital based study from Mid-Western Nepal. *J Clin Diagnostic Res*, 6, 445-448.
- Palmisano L, Vella S. 2011. A brief history of antiretroviral therapy of HIV infection: success and challenges. *Ann 1st Super Sanita*. 44-8.
- Phillips, EJ., Mallal, SA. 2009. Utility of patch testing inpatients with hypersensitivity syndromes associated with abacavir. *AIDS* 2002; 16: 2223-2225.
- Pichler WJ. 2003. Delayed drug hypersensitivity reactions. *Ann Intern Med.* Oct 21; 139(8): 683-93.

- Prasertvit, P., Chareonyingwattana., Wattanakra. 2017. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity. *Contact Dermatitis*.
- Pudjiati SR. 2016. Hubungan polimorfisme gen HLA dengan alergi obat nevirapine pada penderita HIV/AIDS di Indonesia. *Disertasi*. Universitas Gadjah Mada, Yogyakarta.
- Rajesh, C., Vasudevan, B., Pragasam, V. 2013. Severe cutaneous adverse drug reactions. *Medical Journal Armed Forces India*. 69:375-83.
- Roychowdhury, S., Svensson, CK. 2005. Mechanisms of Drug-induced Delayed-type Hypersensitivity Reactions in the Skin. *AAPS Journal*. 7(4): E834-E846.
- Romano, A., Viola, M., Gaeta, F., Rumi, G. 2008. Patch testing in non-immediate drug eruptions. *Allergy, Asthma, and Clinical Immunology, official journal of the Canadian Society of Allergy and Clinical Immunology*, 4(2). 66-74.
- Romano, A. 2010. Diagnosis and management of drug hypersensitivity reaction. *Journal of Allergy and Clinical Immunology*, 127(3), pp.S67-S73.
- Saag M, Balu R, Phillips E. 2008. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. *Clin Infect Dis*: 46:1111–1118.
- Salam N, Rane S, Das R, Faulkner M, Gund R, Kandpal U, et al. 2012. T cell ageing: Effects of age on development, survival & function. *Indian J Med Res*. 138(5): 595–608.
- Sarfo, F., Maame, A., Betty, N. 2014. Incidence and determinants of nevirapine and efavirenz-related skin rashes in west Africans: Nevirapine's Epitath?
- Santiago, F., Goncalo, M., Vieira, R., Coelho, S., Figueiredo, A. 2010. Epicutaneous patch testing in drug hypersensitivity syndrome (DRESS). *Contact Dermatitis*, 62, 47-53.
- Sastroasmoro, S & Ismael, S. 2011. *Dasar-Dasar Metodologi Penelitian Klinis* 4th ed., Jakarta: CV Agung Seto. 35-71.
- Saverino, G & Zompo, MD. 2004. Adverse drug reactions: role of pharmacogenomics. *Pharmacol Res*. 49: 363-73.
- Setyani., 2018. Peran uji tempel obat dalam penegakan etiologi erupsi obat alergik Berat. *Tesis*. Universitas Gadjah Mada, Yogyakarta
- Sharma, VK., Sethuraman, G., Kumar B. 2001. Cutaneous adverse reactions: Clinical pattern and causative agent: A six-year series from Chandigarh, India. *J Postgrad Med*, 47, 95-99.
- Shear, NH & Knowles SP. 2012. Cutaneous reactions to drugs. In: Wolf K. Et al. *Fitzpatrick's Dermatology in General Medicine*. 8th ed, New York, Mc Graw-Hill co, 41, 485-493.
- Shenton JM, Popovic M, Uetrecht JP. 2007. Nevirapine Hypersensitivity. Pichler WJ (ed): *Drug Hypersensitivity*. Basel, Karger, pp 115–28.
- Shiohara, T., Takahashi, R., Kano, Y. 2007. Drug-Induced Hypersensitivity syndrome and Viral Reactivation dalam. Pichler WJ(ed). *Drug Hypersensitivity*. Karger, Basel. 251-266.

- Sidoroff, A., Halevy, A., Bavinck, J., Vaillant, L., Roujeau J. 2001. Acute generalized exanthematous pustulosis (AGEP)- a clinical reaction pattern. *Journal of Cutaneous Pathology*. 28 (3), 113-119.
- Spiewak R. 2008. Patch testing for contact allergy and allergic contact dermatitis. *Open Allergy J*, 1, 42-51.
- Shiny, T.N., Mahajan, V.K. 2017 Patch testing and cross sensitivity study of adverse cutaneous drug reactions due to anti convulsant. *World Journal of Methodology*, 2017;7 (1):25-32.
- Sullivan, T.J. 1991. Skin testing to detect penicillin allergy. *The Journal of Allergy and Clinical Immunology*, 68(3), 171-180.
- Sushma M, Noel V, Ritika CM, James J, Guido S. 2005. Cutaneous adverse drug reactions: a 9-year study from a South Indian hospital. *Pharmacoepid and Drug Safety*, 14, 567-70.
- Sychinder Schnyder B, Adam J, Rauch A. HLA-B*57:01(+) abacavir-naïve individuals have specific T cells but no patch test reactivity. *J Allergy Clin Immunol* 2013; 132: 756–758.
- Thong, B & Tan, TC. 2011. Epidemiology and risk factors for drug allergy. *Br Clin Pharmacol*, 71, pp.684–700.
- Umopathy S, Pawar A, Bajpai S, Pazare AR, and Ghosh K. 2011. HLA involvement in nevirapine-induced dermatological reaction in antiretroviral-treated HIV-1 patients. *J Pharmacol Pharmacother*.2(2): 114–5
- UNAIDS.2016.US, RI partnership to fight HIV/AIDS continues. HYPERLINK <http://proquest.umi.com.ezproxy.utas.edu.au/pqdlink?Ver=1&Exp> (Accessed: September 15, 2018)
- Vella, S., Schwartlander, B., Sow, SP., Eholie, SP., Murphy, RL. 2012. The history of antiretroviral therapy and of its implementation in resource-limited areas of the world. *AIDS*.1231-41.
- Vikas, C. Jhawar, Vipin, S. Sunil, K. Nancy, M. 2013. Transdermal Drug Delivery Systems: *Int. J. Pharm. Sci. Rev. Res.*, 20(1)
- Vikram, K., Mahajan., Handa, S. 2013. Patch testing in cutaneous adverse drug reactions: Methodology, interpretation, and clinical relevance. *Indian J dermatol*, 79, 836-841
- Warrington, R. & Silviu-dan, F. 2011. Drug Allergy. *Allergy, asthma & clinical immunology*, 7(Suppl), 1-8.
- Weiss. 1993. How does HIV cause AIDS? *Science*. Nov 28 260(5112):1273-9.
- Wooltorton, E. 2004. Health and Drug Alerts *CMAJ*. 170(7): 1091.